Gynecologic Oncology Articles | Page 3

Dose-Dense Adjuvant Chemotherapy Shows Potential in Endometrial Cancer
Dose-dense chemotherapy could be a superior option for adjuvant treatment of endometrial cancer compared with standard chemotherapy.
More Studies Needed to Improve Detection and Classification of Fallopian Tube Tumors
Giampero (John) A. Martignetti, MD, PhD, explains that more large-size clinical trials need to be conducted to answer some of the burgeoning questions in the fallopian tube and ovarian cancer landscape.
FDA Approves First Biosimilar for Cancer Treatment
The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.
Pembrolizumab Plus Lenvatinib Trial in Endometrial Carcinoma Expanded
The phase Ib/II Study 111 examining the combination of pembrolizumab and lenvatinib in women with metastatic endometrial carcinoma has been expanded based on positive interim results.
High Cadmium Levels Linked to Increased Endometrial Cancer Risk
Jane McElroy, PhD, discusses the association between higher cadmium levels and an increased risk of endometrial cancer.
Bevacizumab OS Benefit Confirmed in Cervical Cancer
Adding bevacizumab (Avastin) to chemotherapy improved overall survival for women with cervical cancer, according to final results from the phase III GOG 240 trial.
Adjuvant Chemotherapy Reduces Distant Recurrence Risk in Cervical Cancer
Systemic chemotherapy administered post-surgery reduced the risk for distant recurrence in women with node-positive stage IB-IIB cervical cancer.
Expert Discusses Pathology for Ovarian and Endometrial Cancer
Douglas A. Levine, MD, discusses the role of pathology in endometrial and ovarian cancer, and highlights when a patient should be tested for BRCA mutations.
Nivolumab Active in Advanced Gynecologic Cancers
Nivolumab demonstrated clinical activity in women with recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers.
ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215
The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.
Publication Bottom Border
Border Publication